Boisenews Now

B-cell Lymphoma Pipeline Insights

According to DelveInsight, over 295 leading companies are actively engaged in developing more than 300 treatment therapies for B-cell lymphoma.

B-Cell Lymphoma Overview:

B-cell lymphoma is a type of non-Hodgkin lymphoma (NHL) that originates from B lymphocytes, white blood cells that play a key role in producing antibodies to fight infections. Accounting for around 85% of all NHL cases, B-cell lymphomas encompass several subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. Although each subtype presents distinct clinical features, they are all characterized by the abnormal proliferation of B-cells within the lymphatic system, commonly impacting the lymph nodes, spleen, and bone marrow.

Request for a detailed insights report on B-Cell Lymphoma pipeline insights

“B-Cell Lymphoma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-Cell Lymphoma Therapeutics Market.

Key Takeaways from the B-Cell Lymphoma Pipeline Report

• DelveInsight’s B-Cell Lymphoma pipeline report depicts a robust space with 295+ active players working to develop 300+ pipeline therapies for B-Cell Lymphoma treatment.

• In May 2023, Bristol Myers Squibb reported positive topline results from two studies: TRANSCEND FL, a global Phase 2, open-label, multicenter, single-arm study of Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1, open-label, multicenter, single-arm study of Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met their primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.

• In May 2023, Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies.

• In May 2023, Genmab A/S announced that the U.S. Food and Drug Administration (FDA) approved EPKINLY™ (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma, after two or more lines of systemic therapy.

• In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech, Inc. to continue their collaboration and option agreement under revised terms. As a result, the agreement was terminated, and all collaboration activities were set to wind down by the first quarter of 2023.

• Key B-Cell Lymphoma companies such as Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED, and others are evaluating new drugs for B-Cell Lymphoma to improve the treatment landscape.

• Promising B-Cell Lymphoma pipeline therapies in various stages of development include Lisocabtagene maraleucel, Glofitamab, NKTR-255, Zamtocabtagene autoleucel, MB-CART20.1, AVM0703, LBS-007, and others.

B-Cell Lymphoma Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the B-Cell Lymphoma Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Lymphoma treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-Cell Lymphoma market.

Download our free sample page report on B-Cell Lymphoma pipeline insights

B-Cell Lymphoma Emerging Drugs

• Lisocabtagene maraleucel: Bristol Myers Squibb

• Glofitamab: Hoffmann-La Roche

• NKTR-255: Nektar Therapeutics

• Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH

• MB-CART20.1: Miltenyi Biomedicine GmbH

• AVM0703: AVM Biotechnology

• LBS-007: Lin BioScience, Inc

B-Cell Lymphoma Companies

More than 295 prominent companies are currently developing treatments for B-cell lymphoma. Among these, Denovo BioPharma has drug candidates that have reached the most advanced stage—Phase III clinical trials.

DelveInsight’s report covers around 295+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

B-Cell Lymphoma Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging B-Cell Lymphoma Therapies and Key Companies: B-Cell Lymphoma Clinical Trials and advancements

B-Cell Lymphoma Pipeline Therapeutic Assessment

• B-Cell Lymphoma Assessment by Product Type

• B-Cell Lymphoma By Stage

• B-Cell Lymphoma Assessment by Route of Administration

• B-Cell Lymphoma Assessment by Molecule Type

Download B-Cell Lymphoma Sample report to know in detail about the B-Cell Lymphoma treatment market @ B-Cell Lymphoma Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. B-Cell Lymphoma Current Treatment Patterns

4. B-Cell Lymphoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. B-Cell Lymphoma Late-Stage Products (Phase-III)

7. B-Cell Lymphoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. B-Cell Lymphoma Discontinued Products

13. B-Cell Lymphoma Product Profiles

14. B-Cell Lymphoma Key Companies

15. B-Cell Lymphoma Key Products

16. Dormant and Discontinued Products

17. B-Cell Lymphoma Unmet Needs

18. B-Cell Lymphoma Future Perspectives

19. B-Cell Lymphoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the B-Cell LymphomaO Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/